Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer.


Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer, in particular the first-in-class drug, Enfortumab Vedotin, and the pivotal trial resulting in registration together with promising data in combination with checkpoint inhibitors as well as another ADC, Sacituzumab Govitecan, which targets Trop-2. Prof. Srinivas also discusses the development of ADCs for other GU tumour types.

Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practised in this field now for more than 20 years. She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit. She serves as the Vice-chair on the National Comprehensive Cancer Center (NCCN) panel for prostate cancer and has co-authored numerous publications and book chapters. She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update

Episode

3

of 3

episode
Oncology 
How are new data shaping the landscape in HER2-mutant NSCLC?

Insights from WCLC 2026

Experts
Dr Joshua Sabari
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2026

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology Hemato-oncology 
Myelofibrosis: Navigating unmet needs and overcoming clinical challenges

Expert perspectives on clinical trial highlights from EHA 2026

Experts
Prof. Francesco Passamonti, Prof. Claire Harrison
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Sep 2026

Brought to you by COR2ED Medical Affairs in collaboration with Menarini Stemline. This programme is intended for HCPS outside the UK. MED---2600258